- Borgstrom F, Johnell O, Jonsson B, et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 2004a; 34(6)1064–71
- Borgstrom F, Johnell O, Kanis J A, et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Phar-macoeconomics 2004b; 22(17)1153–65
- Borgstrom F, Jonsson B, Strom O, et al. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting : Based on the results of the SOTI and TROPOS trials. Osteoporos Int 2006a; 17(12)1781–93
- Borgstrom F, Zethraeus N, Johnell O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 2006b; 17(5)637–50
- Borgstrom F, Sobocki P, Strom O, et al. The societal burden of osteoporosis in Sweden. Bone 2007; 40(6)1602–9
- Brazier J E, Green C, Kanis J A. Asystematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 2002; 13(10)768–76
- Briggs A H, Wonderling D E, Mooney C Z. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997; 6(4)327–40
- Brooks R. EuroQol: the current state of play. Health Policy 1996; 37(1)53–72
- Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 2001; 10(7)621–35
- De Laet C E, van Hout B A, Burger H, et al. Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 1999; 10(1)66–72
- Dolan P. Modeling valuations for EuroQol health states. MedCare 1997; 35(11)1095–108
- Dolan P, Torgerson D J. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998; 8(6)611–7
- Gabriel S E, Tosteson A N, Leibson C L, et al. Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002; 13(4)323–30
- Gujarati D N. Basic Econometrics. McGraw Hill, Singapore 1995
- Haentjens P, Autier P, Barette M, et al. The economic cost of hip fractures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. J Bone Joint Surg (Am) 2001; 83(4)493–500
- Janzon M, Levin L A, Swahn E. Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The fast revas-cularisation during in stability in coronary artery disease. Eur Heart J 2002; 23(1)31–40
- Johnell O, Kanis J A, Jonsson B, et al. The burden of hospitalised fractures in Sweden. Osteoporos Int 2005; 16(2)222–8
- Jonsson B, Christiansen C, Johnell O, et al. Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol (Suppl) 1996; 103: 30–8
- Kanis J A, Johnell O, Oden A, et al. Long-term risk of osteo-porotic fracture in Malmo. Osteoporos Int 2000; 11(8)669–74
- Kanis J A, Borgstrom F, Johnell O, et al. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 2005; 16(1)15–25
- Koeck C M, Schwappach D L, Niemann F M, et al. Incidence and costs of osteoporosis-associated hip fractures in Austria. Wien Klin Wochenschr 2001; 113(10)371–7
- Liljegren G, Karlsson G, Bergh J, et al. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann Oncol 1997; 8(8)757–63
- Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int (Suppl 2) 2005; 16: S8–S17
- Melton L J, 3rd, Gabriel S E, Crowson C S, et al. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 2003; 14(5)383–8
- Neter J, Kutner M H, Nachtsheim C J, et al. Applied Linear Statistical Models. McGraw-Hill, Chicago 1996
- Nurmi I, Narinen A, Luthje P, et al. Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients. Arch Orthop Trauma Surg 2003; 123(10)551–4
- Oleksik A, Lips P, Dawson A, et al. Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 2000; 15(7)1384–92
- Reginster J Y, Gillet P, Ben Sedrine W, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 1999; 15(5)507–14
- SBU. Osteoporos-prevention, diagnostik och behandling, rapport Nr 165. Stockholm 2003
- SCB Average hourly prices in the private sector,Statistiska Centralbyån (Statistical Sweden). 2004 cited 2005–01–11, from. http://www.ssd.scb.se/databaser/makro/MainTable.asp?yp=tansss&xu=C9233001&omradekod=AM&omradetext=Arbetsmarknad&lang=1
- Stadsledningskontoret Stockholms stads budgetavräkning. 2003 cited 2005-05-20, from www.stockholm.se
- Strom O, Borgstrom F, Sen S S, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int (epub ahead of print). Copenhagen 2007
- Wackerly D, Mendenhall W, Schaeffer R. Mathematical Statistics with Applications. Duxbury Press, New York 1996
- Wiktorowicz M E, Goeree R, Papaioannou A, et al. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 2001; 12(4)271–8
- Wong M K, Arjandas, Ching L K, et al. Osteoporotic hip fractures in Singapore—costs and patient's outcome. Ann Acad Med Singapore 2002; 31(1)3–7
- Vägverket. Väg verkets samhällsekonomiska kalkymodell. Ekonomisk teori och värderingar. Stockholm 1997
- Zethraeus N, Gerdtham U G. Estimating the costs of hip fracture and potential savings. Int J Technol Assess Health Care 1998; 14(2)255–67
- Zethraeus N, Stromberg L, Jonsson B, et al. The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 1997; 68(1)13–7
- Zethraeus N, Borgström F, Johnell O, et al. Costs and Quality of Life Associated with Osteoporosis Related Fractures -Results from a Swedish Survey. Stockholm 2002
- Zethraeus N, Borgström F, Jönsson B, et al. A reassessment of the cost-effectiveness of hormone replacement therapy in Sweden - results based on the Women's Health Initiative randomised controlled trial. Working Paper Series in Economics and Finance at the Stockholm School of Economics, 2004, Working paper No. 571. 2004; http://swopec.hhs.se/hastef/papers/hastef0571.pdf
- Zethraeus N, Strom O, Borgstrom F. What is the risk of institutionalization after hip fracture?. Poster at ECCEO Vienna Volume 17 Supplement 1 / March 2006
Acta Orthopaedica
Volume 79, 2008 - Issue 2